Prosecution Insights
Last updated: November 04, 2026
Application No. 18/470,740

METHOD AND DEVICE FOR DETERMINING ISCHEMIC INJURIES OF MAMMALIAN ORGANS AND TISSUES

Non-Final OA §101§102§103§112
Filed
Sep 20, 2023
Examiner
SKIBINSKY, ANNA
Art Unit
1635
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nikolai Merkin
OA Round
1 (Non-Final)
39%
Grant Probability
At Risk
1-2
OA Rounds
1y 4m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allowance Rate
270 granted / 691 resolved
-20.9% vs TC avg
Strong +29% interview lift
Without
With
+29.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 6m
Avg Prosecution
32 currently pending
Career history
731
Total Applications
across all art units

Statute-Specific Performance

§101
34.1%
-5.9% vs TC avg
§103
29.0%
-11.0% vs TC avg
§102
4.8%
-35.2% vs TC avg
§112
26.6%
-13.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 691 resolved cases

Office Action

§101 §102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The IDS filed 2/25/2026 and 12/20/2023 have been considered by the Examiner. Priority Applicants have not claimed benefit of priority. The instant filing date of 9/20/2023 will be used for the purposes of search and consideration. Claim Objections Claims 2 and 5 are objected to because of the following informalities: The claims recite an extra “is”. Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-24 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Step 1: Process, Machine, Manufacture or Composition Claims 1-11 are drawn to a method, so a process. Claims 12-24 are drawn to a devices, so a machine. Step 2A Prong One: Identification of an Abstract Idea The claim(s) recite(s): 1. A process of evaluating fluorescence intensity values over time, as in claims and 12. This step can be performed by the human mind and is therefore an abstract idea. 2. Subtracting noise from recorded fluorescence, as in claims 2 and 13. This is step is drawn to math and is therefore an abstract idea. 3. Wherein the method determines standard deviation, maximum and minimum intensity and divides the standard deviation by the maximum and minimum intensity, as in claims, as in claims 3-5 and 14-16. This step is drawn to math and is therefore an abstract idea. 4. approximating photobleaching intensity curves through solving a system of differential equations describing the kinetic model of photobleaching to determine NADH concentration, excitation and strength of NADH reducing enzyme, as in claims 6 and 17. This step is drawn to math because solving a system of differential equations describing a kinetic model is mathematics performed on collected data. The step is therefore an abstract idea. 5. classifying photobleaching intensity curves using a neural network and recovering for each curve a unique set of variables, including NADH concentration, excitatory power, and strength of enzyme, as in claims 7 and 18. This step reads on the abstract idea of classifying photobleaching intensity curves which can be performed by the human mind or with math. The use of a neural network reads on matrix mathematics or the implementation of a computer because the neural network is recited at a high degree of generality. See USPTO Subject Matter Eligibility Guidance, Example 47, Claim 2. 6. extracting the NADH fluorescence at a wavelength of 460 nm before clearing the digital fluorescence waveform from noise. Extracting signal data and subtracting noise is drawn to mathematics and is therefore an abstract idea. Step 2A Prong Two: Consideration of Practical Application The claimed process results in the evaluation of fluorescence from NADH emission. The process results in information per se and does not recite any additional elements that integrate the abstract idea into a practical application. This judicial exception is not integrated into a practical application because the claims do not meet any of the following criteria: An additional element reflects an improvement in the functioning of a computer, or an improvement to other technology or technical field; an additional element that applies or uses a judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition; an additional element implements a judicial exception with, or uses a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim; an additional element effects a transformation or reduction of a particular article to a different state or thing; and an additional element applies or uses the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception. Step 2B: Consideration of Additional Elements and Significantly More The claimed method also recites "additional elements" that are not limitations drawn to an abstract idea. The recited additional elements are drawn to: 1. excitation of NADH fluorescence comprising UV-LED and recording NADH fluorescence, as in claims 1 and 12. 2. exposing tissue to 365 nm wavelength radiation, recording radiation at 460 nm, wherein the radiation is sufficient to obtain photobleaching, as in claims 8-10, 19-20 and 22. 3. UV-LED configured for NADH excitation between 1-50 mJ/mm2, as in claims 12 and 23. 4. UV-LED, a lens, optical filter and camera configured to record NADH fluorescence at at least 50 frames per second and 512 x 512 pixels, as in claims 12 and 24. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because UV-LED photon laser technology for NADH excitation and photomultiplier tubes, detector and photon counting modules for fluorescence detection of 460 nm emitted light is well known, routine and conventional. Cameras, including video cameras for recording fluorescence images with at least 50 frames per second and 512 pixels are also well known. Other elements of the method include a unit with a computer (claim 12) as part of a device for processing fluorescence intensity which is a recitation of generic computer structure that serves to perform generic computer functions that are well-understood, routine, and conventional activities previously known to the pertinent industry. Viewed as a whole, these additional claim element(s) do not provide meaningful limitation(s) to transform the abstract idea recited in the instantly presented claims into a patent eligible application of the abstract idea such that the claim(s) amounts to significantly more than the abstract idea itself. Therefore, the claim(s) are rejected under 35 U.S.C. 101 as being directed to non-statutory subject matter. Claim Rejections - 35 USC § 112-2nd paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3, 6, 10 11, 14, 17, 18 and 22 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 3 recites “the standard deviation of the intensity of the excited fluorescence.” There is lack of antecedent basis for “the excited fluorescence” and therefore it is unclear what “the standard deviation of the intensity of the excited fluorescence” is referring to. Claim 14 recites the same limitation. Claim 6 recites “the kinetic model of photobleaching.” There is lack of antecedent basis for this limitation in the claim. Claim 1 from which claim 6 depends is not directed to establishing a kinetic model of photobleaching and therefore it is not clear what “the kinetic model of photobleaching” is referring to. Claim 17 recites the same limitation. Claim 6 recites “the strength of the NADH reducing enzyme.” There is lack of antecedent basis for this limitation in the claim. The process of claim 1 is not directed to or recite the use of an NADH reducing enzyme. Therefore it is not clear that “the strength” of the enzyme is referring to. Claims 7, 17 and 18 recite the same limitation lacking antecedent basis. Claim 10 recites “the excitation radiation that reaches the surface of object under study.” There is lack of antecedent basis for this limitation in the claim. The claimed process in claim 1 does not recite any surface or object under study. It is therefore unclear what “the ratio of time and specific power of the excitation radiation” is referring to. Claim 22 recites a similar limitation. Claim 11 recites “the dynamics of the emergence and progression of ischemic damage areas.” There is lack of antecedent basis for this limitation in the claim. The claimed process in claim 1 does not recite a process of tracking progression of ischemic damage areas. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 3, 8, 9, 11, 12, 14, 19 and 20-22 are rejected under 35 U.S.C. 102(a) as being anticipated by Butte et al. (US 2022/0276167; IDS filed 2/25/2025). Butte et al. teach (par. 0244) measuring NADH redox state in a tissue sample as compared to another tissue sample which may be healthy or injured; cellular metabolism may be characterized (par. 0245) (i.e. excitation of NADH); Butte et al. teach a lens system (par. 0013) (i.e. a lens), as in claim 1, step (a) and claim 12. Butte et al. teach (par. 0259) continuous monitoring of NADH in a time-resolved spectroscopy system (i.e. recording NADH fluorescence), as in claim 1, step (b) and claim 12. Butte et al. teach (par. 0259 and Figure 18) time-resolved spectroscopy and system for continuous monitoring of NADH by assessing fluctuations in fluorescence emission from NADH and NAD+ (i.e. evaluating fluorescence intensity values over a duration of time), as in claim 1, step (c) and claim 12. Butte et al. teach evaluating standard deviation of the spectra band decay (par. 0274 and 0279)(i.e. determining standard deviation of the excited fluorescence), as in claims 3 and 14. Butte et al. teach various lasers and an LED (par. 0016), light pulse that may be about 360 nm (par. 0046) and a laser pulse that may be between 300 nm to 1100 nm (par. 0062), as in claims 8 and 19. Butte et al. teach NADH fluorescing at 460 nm (par. 0259) and recorded spectral bands of 450 nm to 480 nm (par. 213), as in claims 9 and 21 Butte et al. teach using iterations of sample excitation and data collection (par. 0221) in order to monitor cellular metabolism (par. 0245), as in claim 11. Butte et al. teach a demultiplexer with wavelength splitting filter (par. 0212) and is configured to split optical signal into spectral bands of about 450 or 450 to 480 nm (par. 0213)(i.e. optical filter with a bandpass comprising wavelength of 460 nm), as in claim 20. Butte et al. teach assessment of tissue after injury by determining NADH redox state (par. 0244) and characterizing NADH redox state to determine cell viability in ischemic conditions (par. 0245); Butte et al. teach imaging a brain sample by NADH assessment of an ischemic environment (Figure 18A and par. 0259), as in claim 22. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 2 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Butte et al. as applied to claims 1, 3, 8, 9, 11, 12, 14, 19 and 20-22 above, and further in view of Patwardhan et al. (US 2014/0364745; IDS filed 2/25/2025) Patwardhan et al. teach spectral tissue imaging including capturing dark-light images in order to estimate the dark noise of the detector and subtract that noise from fluorescence images, as in claim 2 and 13. It would have been obvious to one of ordinary skill in the art at the time the invention was made to have combined the teachings of Butte et al. with the teachings of Patwardhan et al. for subtracting noise from fluorescent images. The combination of known elements in Butte et and Patwardhan et al. would yield a predictable result of preprocessing images to increase the signal to noise in the results, for the purpose of studying NADH excitation in tissue. Claims 10 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Butte et al. as applied to claims 1, 3, 8, 9, 11, 12, 14, 19 and 20-22 above, and further in view of Kay et al. (US 2019/0183395; IDS filed 2/25/2025). Kay et al. teach (Abstract) an illumination system for in vivo real time measurement of NADH recovery kinetics with specific pulse sequence to non-destructively photobleach NADH; optimum energy delivery of 23.8 mJ of UV light for measuring photobleaching is taught (par. 0006), which suggests enough time and power of excitation to obtain a photobleaching curve, as in claim 10. Kay et al. teach photobleaching energy between 0 mJ/mm2 to 4.5 mJ/ mm2 (par. 0025), as in claim 23. It would have been obvious to one of ordinary skill in the art at the time the invention was made to have combined the teachings of Butte et al. with the teachings of Kay et al. for photobleaching NADH with the energy levels taught by Kay et al. The combination of known elements in Butte et and Kay et al. would yield a predictable result because both Butte et al. and Kay et al. are concerned with NADH excitation to study tissue condition. Implementing the method of Kay et al. would allow for the study of fluorescence over time, as taught by Butte et al. Claim 24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Butte et al. as applied to claims 1, 3, 8, 9, 11, 12, 14, 19 and 20-22 above, and further in view of Kateb et al. (US 2014/0288433; IDS filed 2/25/2025). Kateb et al. teach evaluating fluorescence changes in NADH (par. 0054-0055) and teach a UV camera with a resolution of 1500 x 2000 pixels (par. 0055), a CCD with 1024 x 1024 pixels at frame rates of 1-30 frames or 1-10 frames per second (par. 0062), as in claim 24. It would have been obvious to one of ordinary skill in the art at the time the invention was made to have combined the teachings of Butte et al. with the teachings of Kateb et al. for implementing a pixel resolution and frame rate such that data is captured with enough clarity (i.e. pixels) and quantity to perform NADH fluorescence analysis of tissue. The combination of Butte et al. and Kateb et al. would yield a predictable result because both teach light excitation and emission detection from NADH. E-mail communication Authorization Per updated USPTO Internet usage policies, Applicant and/or applicant’s representative is encouraged to authorize the USPTO examiner to discuss any subject matter concerning the above application via Internet e-mail communications. See MPEP 502.03. To approve such communications, Applicant must provide written authorization for e-mail communication by submitting the following statement via EFS Web (using PTO/SB/439) or Central Fax (571-273-8300): Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application by video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file. Written authorizations submitted to the Examiner via e-mail are NOT proper. Written authorizations must be submitted via EFS-Web (using PTO/SB/439) or Central Fax (571-273-8300). A paper copy of e-mail correspondence will be placed in the patent application when appropriate. E-mails from the USPTO are for the sole use of the intended recipient, and may contain information subject to the confidentiality requirement set forth in 35 USC § 122. See also MPEP 502.03. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Skibinsky whose telephone number is (571) 272-4373. The examiner can normally be reached on 12 pm - 8:30 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-7035. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Anna Skibinsky/ Primary Examiner, AU 1635
Read full office action

Prosecution Timeline

Sep 20, 2023
Application Filed
Aug 27, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781270
METHOD FOR DETECTING A TARGET ANALYTE IN A SAMPLE USING AN S-SHAPED FUNCTION FOR A SLOPE DATA SET
5y 4m to grant Granted Nov 03, 2026
Patent 12723274
METHOD AND DEVICE FOR FIXED-POINT EDITING OF NUCLEOTIDE SEQUENCE WITH STORED DATA
5y 2m to grant Granted Sep 01, 2026
Patent 12725356
COMPUTATIONAL MODEL TO PERSONALIZE DEFIBRILLATION MECHANISM OF WEARABLE CARDIAC DEFIBRILLATOR
4y 7m to grant Granted Sep 01, 2026
Patent 12694953
SYSTEMS, METHODS, AND MEDIA FOR MOLECULE DESIGN USING MACHINE LEARNING MECHANISMS
4y 12m to grant Granted Jul 28, 2026
Patent 12694949
METHOD AND SYSTEM FOR ANALYZING SEQUENCES
2y 10m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
39%
Grant Probability
68%
With Interview (+29.3%)
4y 6m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 691 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month